Fig. 1: Clinical trial design and pharmacokinetics of antibiotics in the plasma and feces of healthy volunteers (HV). | Nature Communications

Fig. 1: Clinical trial design and pharmacokinetics of antibiotics in the plasma and feces of healthy volunteers (HV).

From: The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers

Fig. 1

A Prospective randomized trial design of 148 HV that included in one of the 12 groups: no ATB control (CTRL) without and with DAV132 alone, CZA or PTZ or CRO alone, or CZA or PTZ or CRO in combination with DAV132. ATB were delivered intravenously for 5 days, while DAV132 was administered orally at two doses either 7.5 g po tid or 12 g po tid for 7 days. B Mean plasma concentration (mg/L) of ceftazidime (left panel) and piperacillin (right panel) measured over 18 h after D5. τ was defined as the time interval between two administrations (8 h for PTZ, 8 h for CZA, 24 h for CRO). C Mean fecal concentration (mg/kg) of ceftazidime (left panel) and piperacillin (right panel) measured over 9 days. AUC of antibiotics concentrations were compared between arms using an ANOVA, followed by pairwise comparisons with a Tukey’s adjustment, n = 11–13 HV per group. ATB antibiotic, AUC area under the curve, CZA ceftazidime-avibactam, D day, po orally, PTZ piperacillin-tazobactam, CRO ceftriaxone, q8h every 8 h, q24hr every 24 hour, rRNA ribosomal RNA, tid three times a day, hashtag 16S rRNA sequencing performed, black diamond, metagenomic sequencing performed. (ns non-significant, ****p < 0.0001). Source data are provided as a Source Data file.

Back to article page